Low Vitamin-D Levels Combined with PKP3-SIGIRR-TMEM16J Host Variants Is Associated with Tuberculosis and Death in HIV-Infected and -Exposed Infants

The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters

Citation
Gupta, A., G. Montepiedra, A. Gupte, B. Zeldow, J. Jubulis, B. Detrick, A. Violari, et al. 2016. “Low Vitamin-D Levels Combined with PKP3-SIGIRR-TMEM16J Host Variants Is Associated with Tuberculosis and Death in HIV-Infected and -Exposed Infants.” PLoS ONE 11 (2): e0148649. doi:10.1371/journal.pone.0148649. http://dx.doi.org/10.1371/journal.pone.0148649.

Published Version
doi:10.1371/journal.pone.0148649

Citable link
http://nrs.harvard.edu/urn-3:HUL.InstRepos:25658483

Terms of Use
This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Low Vitamin-D Levels Combined with PKP3-SIGIRR-TMEM16J Host Variants Is Associated with Tuberculosis and Death in HIV-Infected and -Exposed Infants

Amita Gupta1,2*, Grace Montepiedra3*, Akshay Gupte1,2*, Jennifer Jubulis1, Barbara Detrick1, Avy Violari4, Shabir Madhi5, Raziya Bobat6, Mark Cotton7, Charles Mitchell8, Stephen Spector9*, IMPAACT NWCS113 and P1041 Study Team¶

1 Johns Hopkins University School of Medicine, Baltimore, MD, United States of America, 2 Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States of America, 3 Harvard School of Public Health, Boston, MA, United States of America, 4 Perinatal HIV Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, 5 Medical Research Council: Respiratory and Meningeal Pathogens Research Unit and Department of Science and Technology/National Research Foundation: Vaccine Preventable Diseases, University of the Witwatersrand, Johannesburg, South Africa, 6 Department of Pediatrics, University of KwaZulu-Natal, Durban, South Africa, 7 Children’s Infectious Diseases Clinical Research Unit, Faculty of Medicine and Health Sciences, Stellenbosch University, Stellenbosch, South Africa, 8 University of Miami, Miami, FL, United States of America, 9 University of California San Diego, La Jolla, CA, United States of America

☯ These authors contributed equally to this work.
¶ Membership of the IMPAACT NWCS113 and P1041 Study Team is listed in the Acknowledgments.
* agupta25@jhmi.edu (A. Gupta); saspector@ucsd.edu (SS)

Abstract

Background

This study examined the associations of 25-hydroxyvitamin D and specific host genetic variants that affect vitamin D levels or its effects on immune function, with the risk of TB or mortality in children.

Methods

A case-cohort sample of 466 South African infants enrolled in P1041 trial (NCT00080119) underwent 25-hydroxyvitamin D testing by chemiluminescent immunoassay. Single nucleotide polymorphisms (SNPs) that alter the effect of vitamin D [e.g. vitamin D receptor (VDR)], vitamin D levels [e.g. vitamin D binding protein (VDBP)], or toll like receptor (TLR) expression (SIGIRR including adjacent genes PKP3 and TMEM16J) were identified by real-time PCR. Outcomes were time to TB, and to the composite of TB or death by 192 weeks of follow-up. Effect modification between vitamin D status and SNPs for outcomes was assessed.

Findings

Median age at 25-hydroxyvitamin D determination was 8 months; 11% were breastfed, 51% were HIV-infected and 26% had low 25-hydroxyvitamin D (<32ng/mL). By 192 weeks, 138
incident TB cases (43 definite/probable, and 95 possible) and 26 deaths occurred. Adjusting for HIV status and potential confounders, low 25-hydroxyvitamin D was associated with any TB (adjusted hazard ratio [aHR] 1.76, 95% CI 1.01–3.05; \( p = 0.046 \)) and any TB or death (aHR 1.76, 95% CI 1.03–3.00; \( p = 0.038 \)). Children with low 25-hydroxyvitamin D and \textit{TMEM 16J} rs7111432-AA or \textit{PKP3} rs10902158-GG were at increased risk for probable/definite TB or death (aHR 8.12 and 4.83, \( p < 0.05 \)) and any TB or death (aHR 4.78 and 3.26, \( p < 0.005 \)) respectively; SNPs in \textit{VDBP}, \textit{VDR}, and vitamin D precursor or hydroxylation genes were not. There was significant interaction between low 25-hydroxyvitamin D and, \textit{TMEM 16J} rs7111432-AA (\( p = 0.04 \)) and \textit{PKP3} rs10902158-GG (\( p = 0.02 \)) SNPs.

**Conclusions**

Two novel SNPs, thought to be associated with innate immunity, in combination with low vitamin D levels were identified as increasing a young child’s risk of developing TB disease or death. Identifying high-risk children and providing targeted interventions such as vitamin D supplementation may be beneficial.

**Trial Registration**

ClinicalTrials.gov NCT00080119

---

**Introduction**

Annually, more than 7.6 million children under 15 years of age become infected with \textit{Mycobacterium tuberculosis} (\textit{Mtb}), 650,000 develop tuberculosis disease (TB) and over 74,000 die [1–3]. A substantial number of childhood TB cases and deaths occur in HIV and TB endemic countries among HIV-infected and -exposed children under 5 years who are at high risk for developing severe forms of disseminated TB [4]. Prompt and effective diagnosis of TB in children using currently available diagnostic methods can be challenging [5]. Furthermore, treating severe forms of TB in children is resource intensive and is often associated with considerable morbidity and mortality. Thus, strategies aimed at identifying children who are at high risk of developing TB disease are critical.

In adults, several host factors appear to increase the risk of developing TB or death. For example, low levels of 25-hydroxyvitamin D (i.e. vitamin D insufficiency and deficiency), are associated with increased risk of TB infection, TB disease and severity of disease [6–8]. Although the precise mechanisms through which adequate vitamin D protects against TB are unknown, it is thought to enhance innate immunity by regulating monocyte activation, T-cell suppression and cytokine synthesis [9]. Furthermore, several host genetic single nucleotide polymorphisms (SNPs) impacting the vitamin D binding protein (VDBP) as well as the vitamin D receptor (VDR) have also been linked to increased risk of TB, though with variable quality of evidence [10–14]. More recently, a significant association between SNPs in the single immunoglobulin interleukin 1 (IL-1) receptor (\textit{SIGIRR}, also known as Toll IL-1 receptor 8 [Toll/IL-1R-8, TIR8] region including adjacent SNPs in plakophilin 3 (\textit{PKP3}) and transmembrane 16) (\textit{TMEM16}) were associated with susceptibility to TB in Vietnam [15]. This gene region is associated with innate immune pathways and adaptive immune responses, and acts as a negative regulator of Toll-like-receptor (TLR) signaling which is important in \textit{Mtb} pathogenesis [16, 17]. Interestingly, the antimicrobial activity associated with TLR signaling in
macrophages was shown to be dependent on the vitamin D pathway [18, 19] and the association between low levels of 25-hydroxyvitamin D and TB can be modified by host genotype [8, 20, 21].

Whether the associations between low 25-hydroxyvitamin D, host VDR and other SNPs associated with TB risk in adults are important to pediatric populations, especially those in high TB and HIV burden settings, have not been examined. Young children are more likely to be dependent on innate immunity for control of infections prior to the development of mature adaptive immunity and are at high risk for developing TB and dying [4].

Thus in the current study, we examined the associations between low 25-hydroxyvitamin D and host genetic SNPs, including those in the PKP3-SIGIRR-TMEM16J region that are associated with an increased risk of TB [15], with TB and all-cause mortality among HIV-infected and -exposed infants in South Africa. We identify a novel interaction between serum vitamin D levels and genetic variants within the PKP3-SIGIRR-TMEM16J region, which is strongly associated with TB and death among young children.

Methods
Study design and population
This study had two objectives. First was to measure the prevalence and risk factors of low 25-hydroxyvitamin D in the first year of life. Second was to evaluate the associations between 25-hydroxyvitamin D, specific host SNPs including those in the VDR and VDBP genes as well as those altering innate immunity in the PKP3-SIGIRR-TMEM16J gene region and, probable or definite TB in HIV-infected and -exposed infants in a TB-HIV endemic region. Additional objectives were to evaluate the association between these SNPs and the risk of any TB (possible, probable, definite TB) as well as composite any TB or death (the primary endpoint in P1041). All TB outcomes were assessed up to 192 weeks of follow up. We used a case-cohort design to select 466 infants enrolled in the IMPAACT P1041 trial (Clinical Trials.gov NCT00080119) in South Africa; the details of this trial are described elsewhere [22]. Briefly, P1041 was a Phase II/III, randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy of isoniazid prophylaxis on TB disease and latent Mtb infection free survival in HIV-infected and HIV-exposed, but uninfected infants up to 192 weeks of follow up. The vast majority of the 1351 infants enrolled between 3 and 4 months of age were from three sites in South Africa (Johannesburg, Cape Town, and Durban); the one site in Botswana (Gaborone) contributed <0.5% of participants and was not included in our study. All infants were BCG vaccinated and had no previous known TB exposure. The DSMB recommend study closure after an interim analysis showed futility of the isoniazid prophylaxis in both cohorts.

We used a case-cohort design, which allows for both prevalence estimation of the exposures of interest and multiple outcome assessments without having to test the entire P1041 study population [23, 24]. Of 1,351 P1041 trial infants, 896 were eligible as they had either archived serum/plasma (at least 0.125 ml) or peripheral blood mononuclear cells (PBMCs) available; 818 had both. Samples were obtained from two groups: 1) subcohort group: a randomly selected group of 346 eligible infants with both serum/plasma and PBMC samples; 2) case group: 120 participants not included in the subcohort who experienced the outcomes of interest (TB or death). The subcohort group included children with TB. As is the convention with case-cohort studies, the subcohort was used for prevalence estimation and determination of risk factors for low 25-hydroxyvitamin D. The case group was only included in the assessment of association between 25-hydroxyvitamin D, host variants and outcomes of interest. For these analyses, the case group was combined with the subcohort group to form the case-cohort
sample according to case-cohort design principles (352 for vitamin D analyses and 436 for host SNPs analyses). (Fig 1)

The analysis reported in this manuscript was conceived after completion of the P1041 trial. Study participants were enrolled between December 2004 and June 2008, and laboratory analyses on archived samples were performed in 2013. Written informed consent was obtained from parents or legal guardians on behalf of the children enrolled in our study. Our study was approved by the Institutional Review Boards and Ethics Committees at Johns Hopkins University, University of California San Diego, Stellenbosch University, University of Witwatersrand, Soweto, South Africa and the University of KwaZulu Natal, Durban, South Africa.

Laboratory methods

**Determination of 25-hydroxyvitamin D concentrations.** Total 25-hydroxyvitamin D concentrations were assessed on archived serum from study entry or a study visit closest to entry into P1041 using the Diasorin® chemiluminescent immunoassay. Testing was performed at Johns Hopkins University, an externally quality-assured laboratory. We defined vitamin D sufficient as values \( \geq 32 \) ng/mL, 20 to 31 ng/mL as insufficient, and below 20 ng/mL as deficient [9, 25–27].

![Consort diagram for case-cohort study.](https://example.com/fig1)

**Vitamin D analysis – Total N = 352 (270+82)**
- 29 probable/definite TB, 71 possible TB, 20 deaths, 232 non-cases

**Genetic variant analysis – Total N = 436 (328+108)**
- 43 probable/definite TB, 91 possible TB, 17 deaths, 285 non-cases

**Vitamin D and Genetic variant interaction Analysis – Total N = 353**
**Genotyping.** Using archived PBMCs, we examined SNPs associated with low 25-hydroxyvitamin D located within genes that encode VDBP \([GC(rs2282679), rs7041, rs45588]\), 7-dehydrocholesterol reductase involved in synthesis of a vitamin D precursor molecule \([DHCR7 (rs12785878)]\) and a hepatic enzyme within the P450 subfamily involved in 25-hydroxylation of vitamin D \([CYP2R1(rs10741657)]\). Four VDR SNPs \([Fok-I (rs10736810), Bsm-I (rs1544410), Apa-I (rs7975232) and Taq-I (rs731236)]\) and three SNPs in the \([PKP3-SIGIRR-TMEM16F]\) gene region associated with TB susceptibility \([PKP3 (rs10902158-A/G), PKP3 (rs7105848-T/C), and TMEM16F (rs7111432-G/A)]\) were also assessed by real-time PCR assays at the University of California, San Diego IMPAACT Network Specialty Laboratory.

**Statistical methods**

**Outcome definitions.** Low vitamin D was defined as <32 ng/mL. TB was classified as definite, probable or possible based on the 2004 South African National TB Control Program Guidelines \([28]\). The diagnostic algorithm is described elsewhere \([22]\). A definite case was \(Mtb\) cultured from any site. A probable included at least two clinical criteria in the algorithm plus either positive auramine staining of an induced-sputum or gastric-washing smear or suggestive histologic findings (e.g. caseating granuloma); or positive auramine staining of a gastric washing or induced-sputum smear and a chest radiograph suggestive of TB. A possible case was a clinical algorithm score \(\geq 6\) and a radiograph suggestive of TB, or a positive tuberculin skin test (induration \(\geq 5\) mm in horizontal diameter) and a chest radiograph suggestive of TB \([22]\). Outcome of death included all-cause mortality and was not restricted to deaths due to TB.

**Statistical analysis.** Comparisons in baseline characteristics between infants selected for the subcohort and those not selected among those eligible were assessed using Chi-Square, Fisher’s exact, and Wilcoxon tests, as appropriate. The prevalence of low 25-hydroxyvitamin D and SNPs was calculated among the subcohort and 95% confidence intervals were constructed using Clopper-Pearson exact methodology \([29]\).

Baseline correlates of low 25-hydroxyvitamin D were assessed using Chi-Square tests. Cox Proportional Hazards regression models were built to determine the association between low 25-hydroxyvitamin D and outcomes of interest. We also explored Vitamin D level as a continuous variable in models. Formal tests were performed to check the assumption of proportionality of hazards, and no violations were detected. Models were adjusted for the case-cohort design by using Barlow, Prentice, and Self-Prentice weighting schemes \([23, 24]\). All models included low 25-hydroxyvitamin D as the main exposure of interest, adjusting for HIV status, site, season, sex, WHO weight z-score at baseline, whether or not the child was breastfed, type of housing, the mother having a previous TB diagnosis, age in months at plasma draw date and P1041 randomized treatment group of INH or placebo. Models with probable or definite TB as the outcome of interest did not adjust for whether or not the child was breastfed due to model stability issues. Association between low 25-hydroxyvitamin D and SNPs among the subcohort was assessed using Chi-Square tests. Associations between SNPs and the study outcomes described above were assessed using Cox regression models, adjusting for HIV and vitamin D status, and included models that additionally adjusted for the other covariates described above (except for season and age at plasma draw date). Interactions between SNPs and 25-hydroxyvitamin D status were examined and combinations of 25 hydroxyvitamin D status and SNPs were compared. For all Cox Proportional Hazards regression models involving 25-hydroxyvitamin D status, the plasma draw date (date of earliest available sufficient plasma draw) was the time at which participants were first considered at-risk. However, for cases when polymorphisms were considered without vitamin D status included in the model, participants were considered at-risk beginning at study entry for P1041. We applied the methodology of Mark...
and Katki [30] to construct Kaplan-Meier (K-M) curves using the full case-cohort. This method is equivalent to using Self-Prentice weights when the case-cohort sample size is large, such as in this study. Risk differences were computed as the differences in Kaplan-Meier survival estimates at end of follow-up period for this analysis, and were not adjusted for covariates.

The sample size for the sub-cohort corresponds to a sampling fraction of about 30% of the total cohort size of eligible subjects, since this sampling fraction provides nearly the same power to detect significant hazard ratios for vitamin D deficiency/insufficiency (assuming vitamin D deficiency/insufficiency prevalence of 30%) as when the full cohort of eligible subjects were used in the analysis. Similarly, this sampling fraction provides nearly the same power to detect significant hazard ratios for genetic variants (assuming genotype prevalence in the range 20%-50%) as when the full cohort were used in the analysis.

Tests resulting in p-value < 0.05 are reported as significant and 0.05 < p-value < 0.10 are reported as marginally significant. Adjustments for multiple testing of exposures of interest (vitamin D level, genetic variants, and interactions) within each outcome of interest, using Benjamini-Hochberg approach at false discovery rates of FDR = 0.05 and 0.10, are also reported.

Analyses were performed in SAS, version 9.2. K-M curves were constructed using the NestedCohort package (Version 1.1–2) in R, Version 2.15.1.

Results
Characteristics of study participants
A total of 466 infants comprised the case-cohort sample (346 in the randomly selected subcohort and 120 in the case group meeting outcomes of interest but not in the subcohort). There were 134 TB cases (43 definite or probable and 91 possible cases) and 26 deaths. Of TB cases, 131 were pulmonary and 3 were extrapulmonary. Cause of death included gastroenteritis (n = 7), pneumonia (n = 6), sepsis (n = 3), other (n = 4) and unknown (n = 6). Among the 215 HIV-infected infants in the full case-cohort, 27 (13%) were never on ARVs prior to or during the study, 61 (28%) were on ARVs prior to entering the study and 127 (59%) initiated ARVs during the study, with a median time to ART initiation (from enrollment) of 27 days in the latter group. 169 (90%) infants received either Stavudine, Lamivudine and Lopinavir/ritonavir or Lamivudine, Zidovudine and Lopinavir/ritonavir combination therapy. None of the infants received Efavirenz or Tenofovir based regimes. In the subcohort, 167 (48%) infants were males, 148 (43%) were HIV-infected, 58 (17%) had low birth weight and 39 (11%) were ever breastfed (Table 1). Infants included in the subcohort were similar to those not included but eligible, with the exception of site of enrollment (data not shown). There were significant differences between children eligible (with relevant samples for the data analysis) and those ineligible with respect year of enrollment into P1041 (p-value<0.001), HIV status (p-value<0.001), site of enrollment (p-value<0.001), weight z-score (p-value<0.001), whether there were persons >55 years old in the household or not (p-value = 0.002), housing type (p-value<0.001) and water access (p-value<0.001), and there was marginally significant difference with respect to whether the infant was breastfeeding or not at study entry (p-value = 0.09). (S1 Table)

Prevalence and association of low 25-hydroxyvitamin D with TB and death
The mean age at blood draw for 25-hydroxyvitamin D assessments was 7.59 months. The prevalence of low 25-hydroxyvitamin D was 26% (95%CI 21–32), of which 2% were vitamin D deficient and 24% insufficient. (Table 2) Low 25-hydroxyvitamin D status was associated with
younger age, being female, living in formal houses and birth weight ≥2500 grams (p = 0.048, 0.05, 0.004 and 0.02, respectively). (Table 3)

In analyses only adjusting for HIV status, infants with low 25-hydroxyvitamin D had approximately a 2-fold greater risk of being diagnosed with probable or definite TB (aHR 1.70, 95%CI 1.04–2.74; p = 0.09, not significant), any TB (aHR 1.99, 95%CI 1.25–3.13; p = 0.005, significant), and any TB or death (aHR 2.01; 95%CI 1.31–3.03; p = 0.002, significant) as compared to their vitamin D sufficient counterparts. (Fig 2A) In multivariable analyses, adjusting for HIV, site, season, birth weight, breastfeeding, age at plasma draw, house, and INH/placebo group, low 25-hydroxyvitamin D remained significantly associated with any TB (aHR 1.76, 95%CI 1.01–3.05; p = 0.046) and any TB or death (aHR 1.76, 95%CI 1.03–3.00; p = 0.038).

Table 1. Baseline characteristics of full case-cohort (N = 466).

| Characteristic                  | Full Case-cohort | Random sub-cohort | Non-subcohort cases (N = 120**) |
|--------------------------------|------------------|-------------------|---------------------------------|
|                                | Infants chosen for subcohort (N = 346**) | Case of subcohort? |                                |
|                                | No (N = 302) | Yes (N = 44) |
| Infant                         |                |                  |                                |
| Site                           |                |                  |                                |
| Johannesburg                  | 271(78%)       | 233(77%)         | 38(66%)                        |
| Cape Town                      | 49(14%)        | 47(16%)          | 5(5%)                          |
| Durban                        | 26(8%)         | 22(7%)           | 4(9%)                          |
| Male Sex                      | 167(48%)       | 143(47%)         | 24(55%)                        |
| Mean (sd) age in months        | 3.26(0.30)     | 3.26(0.30)       | 3.30(0.29)                     |
| Range of age in months         | 2.99–3.94      | 2.99–3.94        | 2.99–3.94                      |
| HIV-infected                   | 148(43%)       | 121(40%)         | 27(61%)                        |
| INH Treatment Group            | 159(46%)       | 141(47%)         | 18(41%)                        |
| Birth Weight<2500 gms          | 58(17%)        | 50(17%)          | 8(18%)                         |
| Mean (sd) birth weight         | 2939(562)      | 2951(565)        | 2859(544)                      |
| Range of birth weight          | 600–4350       | 600–4350         | 1360–3800                      |
| Mean (sd)weight z-score        | -0.77(1.43)    | -0.73(1.39)      | -1.10(1.61)                    |
| Range of weight z-score        | -5.84–3.48     | -5.84–3.48       | -5.19–1.21                     |
| Ever breastfed                 | 39(11%)        | 35(12%)          | 4(9%)                          |
| Maternal and Household         |                |                  |                                |
| Mother Ever had TB Diagnosis   | 24(7%)         | 22(7%)           | 2(5%)                          |
| Housing Type                   |                |                  |                                |
| Formal (brick) house           | 241(70%)       | 210(70%)         | 31(70%)                        |
| Informal shack                 | 105(30%)       | 92(30%)          | 13(30%)                        |
| Water access                   |                |                  |                                |
| Running water in home          | 124(36%)       | 108(36%)         | 16(36%)                        |
| Running water on plot          | 162(47%)       | 141(47%)         | 21(48%)                        |
| Communal tap                   | 60(17%)        | 53(17%)          | 7(16%)                         |

*Of the 346 samples, 333 had evaluable vitamin D or genetic polymorphism data.
** Only the 120 non-cohort cases with evaluable vitamin D or genetic polymorphism data are included. The sub-cohort (n = 346) was the random sample from the P1041 trial for whom adequate plasma and peripheral blood samples were available. The random sub-cohort had 44 evaluable cases (16 probable/confirmed, 27 possible and 1 death). There were an additional 120 evaluable cases (27 probable/confirmed, 68 possible and 25 deaths) that contributed to a total evaluable case sample of 164.

doi:10.1371/journal.pone.0148649.t001
| Characteristic                      | n(%**) |
|-----------------------------------|--------|
| 25 hydroxyvitamin D status        |        |
| Low* (<32 ng/mL)                  | 70(26.0%) |
| Deficient (<20 ng/mL)             | 5(1.9%) |
| Insufficient (20–31 ng/mL)        | 65(24.1%) |
| Sufficient (≥ 32 ng/mL)           | 200(74.1%) |
| Missing                           | 76(NA) |
| TMEM16J Genotype (rs7111432)      |        |
| AA                                | 83(25.3%) |
| AG                                | 180(54.9%) |
| GG                                | 65(19.8%) |
| PKP3 Genotype (rs10902158)        |        |
| AA                                | 32(9.8%) |
| AG                                | 153(46.6%) |
| GG                                | 143(43.6%) |
| PKP3 Genotype (rs7105848)         |        |
| CC                                | 31(9%) |
| CT                                | 140(43%) |
| TT                                | 157(48%) |
| CYP2R1 Genotype (rs10741657)      |        |
| AA                                | 13(4.0%) |
| AG                                | 100(30.5%) |
| GG                                | 215(65.6%) |
| DHCR7 Genotype (rs12785878)       |        |
| GG                                | 218(66.5%) |
| GT                                | 98(29.9%) |
| TT                                | 12(3.7%) |
| VDBP Genotype (rs2282679)         |        |
| AA                                | 287(87.5%) |
| AC                                | 39(11.9%) |
| CC                                | 2(0.6%) |
| VDBP Genotype (rs4588)            |        |
| AC                                | 36(11.0%) |
| CC                                | 292(89.0%) |
| VDBP Genotype (rs7041)            |        |
| GG                                | 3(0.9%) |
| GT                                | 39(11.9%) |
| TT                                | 286(87.2%) |
| VDR bsm Genotype (rs1544410)      |        |
| AA                                | 14(4.3%) |
| AG                                | 115(35.1%) |
| GG                                | 199(60.7%) |
| VDR fok-1 Genotype (rs10736810)   |        |
| CC                                | 227(69.2%) |
| CT                                | 91(27.7%) |

(Continued)
For the outcome of any TB or death, the survival (K-M) curve for infants with low vitamin D levels was significantly lower than those with normal vitamin D levels (unadjusted risk difference 0.26, 95%CI 0.08–0.44; Fig 3A).

We assessed vitamin D as a continuous variable in models on all outcomes of interest, ignoring the vitamin D polymorphisms, but found no significant result (data not shown).

Prevalence and association of SNPs with vitamin D levels, TB and death

The prevalence of allelic frequencies of SNPs assessed is shown in Table 2. None of the SNPs evaluated were associated with an increased risk of low 25-hydroxyvitamin D (S2 Table). Additionally, no SNPs examined within the VDBP (rs2282679, rs4588, rs7041), VDR (rs10736810, rs1544410, rs7975232, rs731236) or those reportedly associated with vitamin D levels (rs12785878, rs10741657) significantly altered the risk for any TB or death (S3 Table). There were, however, marginally significant associations between rs7041 and probable/definite TB or death (aHR 3.25, 95%CI 0.95–11.1; p = 0.06; S3 Table).

In contrast to the findings relating to the vitamin D related SNPs, SNPs within the PKP3-SIGIRR-TMEM16J region significantly altered the risk for TB or death. In crude and adjusted Cox models, having the TMEM16J (rs7111432) AA-allele was associated with approximately a two-fold-increased risk of probable or definite TB (aHR 1.93, 95%CI 0.96–3.85; p = 0.06, marginally significant), any TB (aHR 1.75, 95%CI 0.91–3.37; p = 0.095, marginally significant) and any TB or death (aHR 1.70, 95%CI 1.10–2.61; p = 0.016, significant). (Fig 2B) Similarly, having the PKP3 (rs10902158) GG-allele was marginally associated with an increased risk of any TB or death (aHR 1.44 95% CI 0.97–2.14; p = 0.07).(Fig 2C)

Low 25-hydroxyvitamin D status with SNPs in the PKP3-SIGIRR-TMEM16J region genetic variants identify infants at high risk for TB and death

We next examined whether infants with low 25-hydroxyvitamin D who also had specific SNPs within the PKP3-SIGIRR-TMEM16J region would be at greater risk for TB or death. We hypothesized that there would be an increased risk for TB or death because vitamin D has an important role in innate immunity through autophagy induction [31, 32] and SNPs within the PKP3-SIGIRR-TMEM16J region impair the down-regulation of toll-like receptor IL-1R signaling, a pathway critical to host immune responses to Mtb [15]. Consistent with our hypothesis, there was a significant interaction between vitamin D status (low 25-hydroxyvitamin D or not) and TMEM16J rs7111432 variants (GG genotype or not) in the adjusted models for any TB (p = 0.04) and any TB or death (p = 0.04). There was also a significant interaction between vitamin D status and PKP3 rs10902158 variants (AA genotype or not) in the adjusted models for any TB or death (p = 0.02).

Table 2. (Continued)

| Characteristic                  | n(%) ** |
|--------------------------------|---------|
| TT                             | 10(3.1%)|

*Vitamin D Insufficient or Deficient.
**Observed prevalence (excluded missing values in denominator).
***Missing genotype data for 18 subjects from sub-cohort of N = 346.

doi:10.1371/journal.pone.0148649.t002
With combinations of vitamin D status and TMEM 16J rs7111432 variants as independent variables in adjusted Cox proportional hazard models, we found that infants with low 25-hydroxyvitamin D and rs7111432-AA genotype had more than a 6-fold increased risk of probable or definite TB (aHR = 6.54, 95%CI 1.07–39.83 p = 0.04, significant) and 8-fold

Table 3. Risk factors for low Vitamin D (25 hydroxyvitamin D) concentrations among the sub-cohort participants.

| Characteristic                          | Total (N = 270) | Without low Vit D (N = 200) | With low Vit D (N = 70) | P-Value |
|-----------------------------------------|-----------------|-----------------------------|------------------------|---------|
| Site                                    | 0.41**          |                             |                        |         |
| Johannesburg                           | 233             | 170(73%)                    | 63(27%)                |         |
| Cape Town                               | 12              | 11(92%)                     | 1(8%)                  |         |
| Durban                                  | 25              | 19(76%)                     | 6(24%)                 |         |
| Infant characteristics                  |                 |                             |                        |         |
| Mean age at draw date, months (s.d.)   | 7.59(1.93)      | 7.72(1.83)                  | 7.21(2.18)             | 0.048*  |
| Sex                                     |                 |                             |                        | 0.05**  |
| Male                                    | 128             | 102(80%)                    | 26(20%)                |         |
| Female                                  | 142             | 98(69%)                     | 44(31%)                |         |
| HIV Status                              |                 |                             |                        | 1.00**  |
| HIV-infected                            | 138             | 102(74%)                    | 36(26%)                |         |
| HIV-uninfected                          | 132             | 98(74%)                     | 34(26%)                |         |
| Birth Weight<2500 gms                   |                 |                             |                        | 0.018** |
| Yes                                     | 49              | 43(88%)                     | 6(12%)                 |         |
| No                                      | 221             | 157(71%)                    | 64(29%)                |         |
| Mean weight z-score (WHO) (s.d.)        | -0.90(1.47)     | -0.94(1.47)                 | -0.80(1.49)            | 0.45*   |
| Ever breastfed?                         |                 |                             |                        | 1.00**  |
| Yes                                     | 31              | 23(74%)                     | 8(26%)                 |         |
| No                                      | 239             | 177(74%)                    | 62(26%)                |         |
| Season of sample for Vitamin D          |                 |                             |                        | 0.13**  |
| April-Sept                              | 125             | 87(70%)                     | 38(30%)                |         |
| Oct-March                               | 145             | 113(78%)                    | 32(22%)                |         |
| Mother Ever had TB Diagnosis            |                 |                             |                        | 0.25**  |
| Yes                                     | 16              | 14(88%)                     | 2(13%)                 |         |
| No                                      | 254             | 186(73%)                    | 68(27%)                |         |
| Household characteristics               |                 |                             |                        |         |
| >3 people sleep in room                 |                 |                             |                        | 0.68**  |
| Yes                                     | 106             | 76(72%)                     | 30(28%)                |         |
| No                                      | 163             | 123(75%)                    | 40(25%)                |         |
| Not known                               | 1               | 1(100%)                     | 0(0%)                  |         |
| Any 55 year olds in house?             |                 |                             |                        | 0.44**  |
| Yes                                     | 78              | 55(71%)                     | 23(29%)                |         |
| No                                      | 192             | 145(76%)                    | 47(24%)                |         |
| Housing Type                            |                 |                             |                        | 0.004** |
| Formal (brick) house                    | 190             | 131(69%)                    | 59(31%)                |         |
| Informal shack                          | 80              | 69(86%)                     | 11(14%)                |         |
| Water access                            |                 |                             |                        | 0.07**  |
| Running water in home                   | 94              | 67(71%)                     | 27(29%)                |         |
| Running water on plot                   | 134             | 96(72%)                     | 38(28%)                |         |
| Communal tap                            | 42              | 37(88%)                     | 5(12%)                 |         |

*Wilcoxon test.
**Chi-square test.

doi:10.1371/journal.pone.0148649.t003
Fig 2. Cox Proportional Hazard Models for TB disease or death, looking at (A) low vitamin D (LVD) status as risk factor ignoring genetic variant, (B) TMEM16J rs7111432 variant as risk factor ignoring LVD status, and (C) PKP3 rs10902158 variant as risk factor ignoring LVD status. Model 1 adjusts for HIV infection status. Model 2 adjusts for HIV status, season, site, sex, weight z-score, type of house, mother prev TB diagnosis, age (in months) at plasma draw date, and INH/Placebo group. Model 3 adjusts for HIV status, site, sex, weight z-score, type of house, mother prev TB diagnosis, and INH/Placebo group. Evts/LVD = no. of events/no. of subjects with low vitamin D (%). Evts/NotLVD = no. of events/no. of subjects without low vitamin D (%). Evts/AA = no. of events/no. of subjects with AA genotype (%). Evts/NotAA = no. of events/no. of subjects without AA genotype (%). Evts/GG = no. of events/no. of subjects with GG genotype (%). Evts/NotGG = no. of events/no. of subjects without GG genotype (%). doi:10.1371/journal.pone.0148649.g002
increased risk of probable/definite TB or death (HR = 8.12 95% CI 1.85–35.67 p = 0.006, significant) compared to those without low vitamin D and without AA genotype. When including possible TB events, the risk remained more than 4-fold increased (any TB HR = 4.19 95% CI 1.79–9.83 p = 0.001, significant; and any TB or death HR = 4.78 95% CI 2.06–11.09 p = 0.0003, significant). (Fig 4A) Adjusting for multiple testing, and using a false discovery rate of FDR = 0.05, the comparison of risk of any TB or death between subjects with combination of LVD / rs7111432-AA genotype versus those with combination of not LVD / rs7111432-not AA genotype remained significant. For any TB or death, the K-M plot shows a much lower survival curve among infants with low vitamin D levels and with the AA genotype compared to the three more similar curves representing the other combinations (e.g., unadjusted risk difference versus infants with normal vitamin D level and with the AG/GG genotype is 0.34 with 95%CI 0.12–0.56; Fig 3B).
A Hazard ratios (HR) for low Vitamin D (LVD) status and *TMEM16J* rs7111432 polymorphism combinations

| Outcome or Event | Risk factor Combination | Total | Events (%) | HR (95% CI) | P-value |
|------------------|-------------------------|-------|------------|-------------|---------|
| Probable/Definite | Overall                 | 271   | 29 (11%)   |             | 0.456   |
|                  | LVD/AA                  | 14    | 3 (21%)    | 3.79 (0.72-20.12) | 0.117   |
|                  | LVD/NOT AA              | 57    | 7 (12%)    | 1.33 (0.42-4.19)  | 0.624   |
|                  | Not LVD/AA              | 57    | 7 (12%)    | 1.34 (0.40-5.45)  | 0.639   |
|                  | Not LVD/NOT AA          | 143   | 12 (8%)    |             |         |
| Probable/Definite TB or Death | Overall | 282   | 40 (14%)  |             | 0.044   |
|                  | LVD/AA                  | 17    | 6 (35%)    | 8.12 (1.85-35.67) | 0.006   |
|                  | LVD/NOT AA              | 60    | 10 (17%)   | 1.08 (0.41-2.68)  | 0.880   |
|                  | Not LVD/AA              | 57    | 7 (12%)    | 0.67 (0.19-2.43)  | 0.550   |
|                  | Not LVD/NOT AA          | 148   | 17 (11%)   |             |         |
| Any TB | Overall                 | 381   | 96 (27%)   |             | 0.010   |
|                  | LVD/AA                  | 27    | 12 (49%)   | 4.19 (1.79-9.83)  | 0.001   |
|                  | LVD/NOT AA              | 76    | 21 (28%)   | 1.26 (0.65-2.49)  | 0.490   |
|                  | Not LVD/AA              | 74    | 20 (27%)   | 1.22 (0.59-2.53)  | 0.600   |
|                  | Not LVD/NOT AA          | 184   | 43 (23%)   |             |         |
| Any TB/Death | Overall                 | 372   | 107 (29%)  |             | 0.003   |
|                  | LVD/AA                  | 30    | 15 (50%)   | 4.78 (2.06-11.09) | <0.001  |
|                  | LVD/NOT AA              | 79    | 24 (30%)   | 1.20 (0.62-2.31)  | 0.590   |
|                  | Not LVD/AA              | 74    | 20 (27%)   | 1.22 (0.59-2.53)  | 0.830   |
|                  | Not LVD/NOT AA          | 189   | 48 (25%)   |             |         |

B Hazard ratios (HR) for low Vitamin D (LVD) status and *PKP3* rs10902158 polymorphism combinations

| Outcome or Event | Risk factor Combination | Total | Events (%) | HR (95% CI) | P-value |
|------------------|-------------------------|-------|------------|-------------|---------|
| Probable/Definite | Overall                 | 271   | 29 (11%)   |             | 0.465   |
|                  | LVD/GG                  | 28    | 6 (21%)    | 2.71 (0.62-11.81) | 0.185   |
|                  | LVD/NOT GG              | 42    | 4 (10%)    | 0.96 (0.25-3.63)  | 0.947   |
|                  | Not LVD/GG              | 90    | 8 (9%)     | 1.08 (0.33-3.53)  | 0.903   |
|                  | Not LVD/NOT GG          | 110   | 11 (10%)   |             |         |
| Probable/Definite TB or Death | Overall | 282   | 40 (14%)  |             | 0.090   |
|                  | LVD/GG                  | 33    | 10 (30%)   | 4.83 (1.26-18.50) | 0.022   |
|                  | LVD/NOT GG              | 44    | 6 (14%)    | 1.00 (0.31-3.27)  | 0.990   |
|                  | Not LVD/GG              | 94    | 13 (13%)   | 1.38 (0.47-4.01)  | 0.560   |
|                  | Not LVD/NOT GG          | 144   | 36 (25%)   |             |         |
| Any TB | Overall                 | 381   | 96 (27%)   |             | 0.030   |
|                  | LVD/GG                  | 50    | 22 (44%)   | 2.73 (1.29-5.76)  | 0.069   |
|                  | LVD/NOT GG              | 83    | 11 (21%)   | 0.89 (0.40-1.96)  | 0.770   |
|                  | Not LVD/GG              | 114   | 27 (24%)   | 1.01 (0.53-1.90)  | 0.990   |
|                  | Not LVD/NOT GG          | 144   | 36 (25%)   |             |         |
| Any TB/Death | Overall                 | 372   | 107 (29%)  |             | 0.010   |
|                  | LVD/GG                  | 54    | 26 (48%)   | 3.26 (1.54-6.93)  | 0.002   |
|                  | LVD/NOT GG              | 55    | 13 (24%)   | 0.98 (0.46-2.11)  | 0.960   |
|                  | Not LVD/GG              | 118   | 31 (26%)   | 1.10 (0.59-2.05)  | 0.760   |
|                  | Not LVD/NOT GG          | 145   | 37 (26%)   |             |         |

Fig 4. Cox Proportional Hazard Models for TB disease or death, looking at (A) combination of low Vitamin D (LVD) status and *TMEM16J* rs7111432 variant [AA genotype or not] as risk factor, and (B) combination of LVD status and *PKP3* rs10902158 variant [GG genotype or not] as risk factor. A: Model adjusts for HIV status, season, site, sex, weight z-score, type of house, mother with previous TB diagnosis, age (in months) at plasma draw date, and INH/Placebo group. B: Model adjusts for HIV status, season, site, sex, weight z-score, type of house, mother with previous TB diagnosis, age (in months) at plasma draw date, and INH/Placebo group.

doi:10.1371/journal.pone.0148649.g004
Similarly, models fitted with a combination of vitamin D status and \(\text{PKP3}\) rs10902158 variants as independent variables demonstrated that having low 25-hydroxyvitamin D and rs10902158-GG genotype had a significantly higher risk of probable/definite TB or death (aHR = 4.83, 95%CI 1.26–18.50; \(p = 0.02\)) as well as any TB (aHR 2.73, 95%CI 1.29–5.75; \(p = 0.009\)) or any TB or death (3.26, 95%CI 1.54–6.93; \(p = 0.002\)). (Fig 4B) Adjusting for multiple testing, and with an FDR = 0.10, the comparison of risk of any TB or death between subjects with combination of LVD / rs10902158-GG genotype versus those with combination of not LVD / rs10902158-not GG genotype remained significant. For the outcome of any TB or death, the K-M plots are shown in Fig 3C shows the much lower survival curve among infants with low vitamin D levels and with the rs10902158-GG genotype compared to the three more similar curves representing the other combinations (e.g., unadjusted risk difference versus infants with normal vitamin D level and with the AA/AG genotype is 0.56 with 95%CI 0.43–0.68).

**Discussion**

This study has several key findings. First, 26% of young children residing in a high TB and HIV burden setting had low levels of 25-hydroxyvitamin D. Second, low 25-hydroxyvitamin D below 32 ng/mL was associated with a 1.7-fold increased risk for TB and death independent of host variants. Third, we demonstrate that genetic variants within the \(\text{PKP3-SIGIRR-TMEM16J}\) gene region (\(\text{PKP3-rs10902158-A/G}\) and \(\text{TMEM16J-rs7111432 G/A}\)) are significantly associated with a 40% to 70% increased risk for pediatric TB and death. Lastly, the most intriguing and relevant finding was the interaction between low 25-hydroxyvitamin D and \(\text{PKP3-SIGIRR-TMEM16J}\) host variants. To our knowledge, we demonstrate for the first time that young children with both low 25-hydroxyvitamin D and the rs7111432-AA have a 4- to 8-fold increased risk of TB or death. Similarly, those with both low 25-hydroxyvitamin D and rs10902158-GG genotypes have a 3- to 4-fold increased risk for developing TB or dying. It is likely that such effect modifying variants will have important implications for vitamin D supplementation strategies. Vitamin D supplementation may have greatest benefit in preventing TB in children with both low levels of 25-hydroxyvitamin D and \(\text{PKP3-SIGIRR-TMEM16J}\) host variants reported in our study.

We observed that 26% of infants were vitamin D insufficient or deficient. This prevalence is lower than reported elsewhere [33]. In agreement with the infant feeding policy for HIV exposed infants in South Africa at the time the study was conducted, a high proportion of the children in our study were fed vitamin D fortified formula. As would be expected, few infants were identified to be vitamin D deficient using the criterion of <20 ng/mL. For the purposes of immunologic health, we apriori used a value of \(\geq 32\) ng/mL 25-hydroxyvitamin D as sufficient. In support of using a higher value of vitamin D for optimal immunologic health, Campbell and Spector demonstrated that the activity of vitamin D3 against \(\text{Mtb}\) follows a dose response with higher concentrations providing greater killing of the organism [34].

Low levels of vitamin D has long been implicated in the susceptibility to TB [35]. In our study, children with low 25-hydroxyvitamin D had a 70% increased risk of developing any TB or death. Molecular mechanisms responsible for the activity of vitamin D against \(\text{Mtb}\) are the subject of considerable research [8]. For children who are infected with \(\text{Mtb}\) but do not develop disease, the infectious organisms can remain within the phagosomes of macrophages and may not reactivate for decades [9]. \(\text{Mtb}\) prevents the acidification of the phagosomes preventing the maturation to phagolysosomes and the degradation of the mycobacteria. The trafficking pathway whereby cytoplasmic constituents, including sub-cellular organelles, and microbial pathogens, such as \(\text{Mtb}\), are engulfed by phagosomes (or autophagosomes) which fuse with
lysosomes forming phagolysosomes (or autolysosomes) leading to bulk degradation is termed autophagy. Numerous studies have demonstrated that the induction of autophagy in vitro can kill Mtb [31, 32]. In this regard, the active form of vitamin D (1,25D3) can induce autophagy with the anti-mycobacterial activity dependent on the induction of autophagy and the expression of endogenous human cathelicidin microbial peptide [34].

Host genetic variations can alter both the risk for respiratory disease and severity of infection [9, 36]. Several studies have assessed the relationship between host genetic variants and TB [37, 38]. The vast majority of these studies were conducted in adults, and association between host genetic variants and risk of TB in pediatric populations remains unknown [8, 14]. A meta-analysis of 23 studies showed an increased risk for TB associated with VDR polymorphisms [12]. The Ff genotypes of FokI polymorphism were associated with increased risk and the bb genotype of BsmI genotype with decreased risk of TB. Interestingly, this was only observed in Asian populations. There does not appear to be an association between polymorphisms in CYP27B1 which encodes 25-hydroxyvitamin D3 1-alpha-hydroxylase, an enzyme catalyzing the hydroxylation of 25-hydroxyvitamin D to 1,25-dihydroxyvitamin D (the bioactive form of vitamin D)[39]. Our study extends these findings to pediatric populations in high TB and HIV burden settings. Children expressing the TMEM16j (rs7111432) AA-allele or the PKP3 (rs10902158) GG-allele had a nearly 2-fold increased risk of any TB or death. However, we did not find a significant association between CYP27B1, rs7041, Fok1 and BsmI SNPs and risk of TB or death. We did however find a trend towards significance with VDBP rs7041 and probable/definite TB or death, not found when adding possible TB to the outcome. The low prevalence of the rs7041 GG/GT allele (43/346, 12.8%) may have contributed to the lack of consistency in direction of results for this SNP, but the presence of some signals in this cohort suggests the need for further study of this particular SNP in larger cohorts.

The modification of the association between host genetic variants and TB by vitamin D status has been observed in a series of studies in adults. Increased TB risk in adults was associated with the TT or Tt alleles of TaqI and the ff allele of FokI, but only in persons with vitamin D deficiency [10]. However while Gc genotypes (which are encoded in the VDBP) are not generally associated with active TB, Martinueau and colleagues observed that the Gc2/2 genotype is strongly associated with development of active TB compared with Gc1 but only in Gujarati Indians and specifically in those with low vitamin D [21]. TLRs play an important role in pathogen recognition and triggering host innate immune responses [40]. Therefore, we hypothesized that genetic variants within the PKP3-SIGIRR-TMEM16j gene region that affect TLR expression recently identified to be associated with susceptibility to TB would exacerbate the risk of TB in children with low vitamin D levels. Our findings support this supposition and demonstrate a strong synergy between low vitamin D levels and specific SNPs within the PKP3-SIGIRR-TMEM16j gene region, and the risk for TB and death among children. Young children in our study with both low vitamin D levels and rs7111432-AA or rs10902158-GG genotypes had a 3- to 8-fold increased risk of TB or death, an association much higher than that observed for low vitamin D concentrations or PKP3-SIGIRR-TMEM16j SNPs alone. It is therefore possible that children with SNPs in the PKP3-SIGIRR-TMEM16j gene region may selectively benefit from anti-mycobacterial activity of vitamin-D and therefore may potentially be prime targets for vitamin-D supplementation.

Our study has a few limitations. The majority of our children were formula fed which at the time was the standard of care in South Africa for HIV-exposed children. Breastfed children tend to have lower vitamin D concentrations than formula fed children as formula has some vitamin D supplementation. Therefore, our prevalence of low vitamin D is likely an underestimate since now the national policy has changed back to promoting exclusive breastfeeding. Our study data were from a well-conducted clinical trial where TB and death were rigorously...
evaluated. However, we noted that many deaths were due to infectious etiologies other than TB (diarrhea, respiratory, sepsis), and therefore our findings are consistent with the fact that the host variants associated with innate immunity were indeed relevant to both TB and other infections. Another limitation to our study is that the genetic associations identified may not be due to \textit{PKP3} or \textit{TMEM16J} SNPs. As noted by Horne et al.,\cite{15} the SNPs identified as important in \textit{PKP3} or \textit{TMEM16J} may be in linkage disequilibrium with SNPs within \textit{SIGIRR}. The \textit{SIGIRR} (also known as TIR8) region is a biologically important modulator of TLR-IL-1R signaling, inhibits NF-kappa B, modulates inflammation and in the mouse model has been shown to regulate harmful responses to infections such as TB \cite{16}. The \textit{PKP3/TMEM16J} flank the \textit{SIGIRR} but have unknown functions. Thus it is possible that other SNPs within the \textit{SIGIRR} region are responsible for the direct effects on microbial pathogenesis or that \textit{PKP3/TMEM16J} regions have as yet an unidentified role in innate immunity. Finally, the study participants in this analysis were not fully representative of the parent P1041 study population due to differences in eligibility for analysis with respect to certain participant characteristics and sample availability. However, these differences are unlikely to change our overall interpretation of the associations we detected.

The World Health Organization and United Nations Millennium Development Goals call for dramatic reductions in pediatric TB cases and childhood mortality, respectively. Identifying children at high risk for TB or death therefore is a global priority. We found an association of vitamin D levels with the risk for development of TB or death in HIV-infected and –exposed but uninfected infants in South Africa. Additionally, specific variants within the \textit{PKP3-SIGIRR-TMEM16J} gene region were also associated with risk of TB or death. More importantly, genetic variants combined with low vitamin D status identified infants at highest risk for TB disease or death. These findings suggest that vitamin D supplementation of infants may be of benefit to infants in high TB burden countries, and that children with specific genetic variations may benefit from supplementation to a greater extent. Clinical trials are needed to evaluate the benefits of supplemental vitamin D in high-risk settings.

Supporting Information

S1 Table. Comparison between P1041 participants with plasma/PBMC samples (eligible for subcohort) and those without.

(DOCX)

S2 Table. Genetic polymorphisms by vitamin D status among subcohort.

(DOCX)

S3 Table. Adjusted hazard ratios of other genetic polymorphisms as potential risk factors for study outcomes. Models adjust for HIV status, sex, mother TB diagnosis history, type of housing, breastfeeding (excluded in model for probable or definite TB), weight z-score, site, and randomized treatment group (INH or placebo) * CI: Confidence interval.

(DOCX)

Acknowledgments

We thank the P1041 study team; and the parents/legal guardians for allowing their children to participant in this study. We would also like to thank Bruno Andrade for his assistance in preparing Figs 2 and 4. Overall support for the International Maternal Pediatric Adolescent AIDS Clinical Trials Group (IMPAACT) was provided by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) under Award Numbers UM1AI068632 (IMPAACT LOC), UM1AI068616 (IMPAACT SDMC) and UM1AI106716
(IMPAACT LC), with co-funding from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) and the National Institute of Mental Health (NIMH). Support of the sites was provided by NIAID and the NICHD International and Domestic Pediatric and Maternal HIV Clinical Trials Network (NICHD contract number N01-DK-9-001/HHSN267200800001C), NIAID UM1AI069465 (Gupta A.) and NINDS 5R01NS077874 (Spector S.A.). The Ujala Foundation also supported Gupte A. and Gupta A. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.

The P1041 study team in alphabetical order—Anchilla Owor, Avye Violari, Barbara Nowak, Charles D. Mitchell, Chengcheng Hu, Courtney Ashton, Courtney Fletcher, Elizabeth Hawkins, Emily Barr, Enbavani Pillay, Francis Martinson, George McSherry, Hendrik Simon Schaaf, James Reuben, Jennifer Kiser, Jennifer S. Read, Joan Coetzee, Lynette Purdue, Marianne Kohler, Mark Abzug, Mark Cotton, Mina Hosseinipour, Patrick Jean-Philippe, Peter Roderick Donald, Raziya Bobat, Shabir Madhi, Sharon A. Nachman, Soyeon Kim, Walter Scott, William Kabat.

Shabir Madhi (Email: shabirm@nicd.ac.za) and Charles Mitchell (Email: cmitchel@med.miami.edu) are the lead authors for the P1041 study team.

Author Contributions

Conceived and designed the experiments: A. Gupta SS. Performed the experiments: BD SS AV MC RB JJ SM CM. Analyzed the data: GM BZ. Wrote the paper: A. Gupte A. Gupta SS GM. Contributed to the statistical design of the study: GM BZ. Secured funding for the parent study: SM CM. Secured funding for the current study: A. Gupta SS. Read and approved the final version of the report: A. Gupta GM A. Gupte BZ JJ BD AV SM RB MC CM SS.

References

1. Dodd PJ, Gardiner E, Coghlan R, Seddon JA. Burden of childhood tuberculosis in 22 high-burden countries: a mathematical modelling study. Lancet Glob Health. 2014; 2(8):e453–9. doi:10.1016/S2214-109X(14)70245-1 PMID: 25103518.

2. Hesseling AC, Cotton MF, Jennings T, Whitelaw A, Johnson LF, Eley B, et al. High incidence of tuberculosis among HIV-infected infants: evidence from a South African population-based study highlights the need for improved tuberculosis control strategies. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2009; 48(1):108–14. doi:10.1086/595012 PMID: 19049436.

3. WHO. Global Tuberculosis Report Geneva, Switzerland: World Health Organization 2013.

4. Perez-Velez CM, Marais BJ. Tuberculosis in children. The New England journal of medicine. 2012; 367(4):348–61. doi:10.1056/NEJMra1008049 PMID: 22830465.

5. Graham SM, Ahmed T, Amanullah F, Browning R, Cardenas V, Casenghi M, et al. Evaluation of tuberculosis diagnostics in children: 1. Proposed clinical case definitions for classification of intrathoracic tuberculosis disease. Consensus from an expert panel. J Infect Dis. 2012; 205 Suppl 2:S199–208. doi:10.1093/infdis/jis008 PMID: 22448023; PubMed Central PMCID: PMC3334506.

6. Martineau AR, Nhamoyebonde S, Oni T, Rangaka MX, Marais S, Bangani N, et al. Reciprocal seasonal variation in vitamin D status and tuberculosis notifications in Cape Town, South Africa. Proc Natl Acad Sci U S A. 2011; 108(47):19013–7. doi:10.1073/pnas.1111825108 PMID: 22025704; PubMed Central PMCID: PMC3223428.

7. Martineau AR, Timms PM, Bothamley GH, Hanifa Y, Islam K, Claxton AP, et al. High-dose vitamin D(3) during intensive-phase antimicrobial treatment of pulmonary tuberculosis: a double-blind randomised controlled trial. Lancet. 2011; 377(9761):242–50. doi:10.1016/S0140-6736(10)61889-2 PMID: 21215445; PubMed Central PMCID: PMC4176755.

8. Ralph AP, Lucas RM, Norval M. Vitamin D and solar ultraviolet radiation in the risk and treatment of tuberculosis. Lancet Infect Dis. 2013; 13(1):77–88. doi:10.1016/S1473-3099(12)70275-X PMID: 23257233.
9. Walker VP, Modlin RL. The vitamin D connection to pediatric infections and immune function. Pediatr Res. 2009; 65(5 Pt 2):106R–13R. doi: 10.1203/PDR.0b013e31819dba91 PMID: 19190532; PubMed Central PMCID: PMC2925470.

10. Wilkinson RJ, Llewelyn M, Toossi Z, Patel P, Pasvol G, Lalvani A, et al. Influence of vitamin D deficiency and vitamin D receptor polymorphisms on tuberculosis among Gujarati Asians in west London: a case-control study. Lancet. 2000; 355(9204):618–21. doi: 10.1016/S0140-6736(99)02301-6 PMID: 10696983.

11. Nnoaham KE, Clarke A. Low serum vitamin D levels and tuberculosis: a systematic review and meta-analysis. Int J Epidemiol. 2008; 37(1):113–9. doi: 10.1093/ije/dyn247 PMID: 18245055.

12. Gao L, Tao Y, Zhang L, Jin Q. Vitamin D receptor genetic polymorphisms and tuberculosis: updated systematic review and meta-analysis. The international journal of tuberculosis and lung disease: the official journal of the International Union against Tuberculosis and Lung Disease. 2010; 14(1):15–23. PMID: 20003690.

13. Lewis SJ, Baker I, Davey Smith G. Meta-analysis of vitamin D receptor polymorphisms and pulmonary tuberculosis risk. The international journal of tuberculosis and lung disease. 2005; 9(10):1174–7. PMID: 16229232.

14. Valdivielso JM, Fernandez E. Vitamin D receptor polymorphisms and diseases. Clin Chim Acta. 2006; 371(1–2):1–12. doi: 10.1016/j.cca.2006.02.016 PMID: 16563362.

15. Horne DJ, Randhawa AK, Chau TT, Bang ND, Yen NT, Farrar JJ, et al. Common polymorphisms in the PKP3-SIGIRR-TEMEM16J gene region are associated with susceptibility to tuberculosis. The Journal of infectious diseases. 2012; 205(4):856–94. doi: 10.1093/infdis/jir785 PMID: 22223854; PubMed Central PMCID: PMC3266131.

16. Garlenda C, Dinarello CA, Mantovani A. The interleukin-1 family: back to the future. Immunity. 2013; 39(6):1003–18. doi: 10.1016/j.immuni.2013.11.010 PMID: 23516984.

17. O’Garra A, Redford PS, McNab FW, Bloom CI, Wilkinson RJ, Berry MP. The immune response in tuberculosis. Annu Rev Immunol. 2013; 31:475–527. doi: 10.1146/annurev-immunol-032712-095939 PMID: 23516984.

18. Campbell GR, Spector SA. Toll-like receptor 8 ligands activate a vitamin D mediated autophagic response that inhibits human immunodeficiency virus type 1. PLoS Pathog. 2012; 8(11):e1003017. doi: 10.1371/journal.ppat.1003017 PMID: 23166493; PubMed Central PMCID: PMC3499571.

19. Liu PT, Stenger S, Li H, Wenzel L, Tan BH, Krutzik SR, et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science. 2006; 311(5768):1770–3. doi: 10.1126/science.1123933 PMID: 16497887.

20. Levin GP, Robinson-Cohen C, de Boer IH, Houston DK, Lohman K, Liu Y, et al. Genetic variants and associations of 25-hydroxyvitamin D concentrations with major clinical outcomes. JAMA. 2012; 308(18):1898–905. doi: 10.1001/jama.2012.17304 PMID: 23150009; PubMed Central PMCID: PMC3645444.

21. Martineau AR, Leandro AC, Anderson ST, Newton SM, Wilkinson KA, Nicol MP, et al. Association between Gc genotype and susceptibility to TB is dependent on vitamin D status. Eur Respir J. 2010; 35(5):1106–12. doi: 10.1183/09031936.00070909 PMID: 19797126; PubMed Central PMCID: PMC2864196.

22. Madhi SA, Nachman S, Violari A, Kim S, Cotton MF, Bobat R, et al. Primary isoniazid prophylaxis against tuberculosis in HIV-exposed children. The New England journal of medicine. 2011; 365(1):21–31. doi: 10.1056/NEJMoa1112124 PMID: 21732854; PubMed Central PMCID: PMC3164539.

23. Prentice RL. A case-cohort design for epidemiologic cohort studies and disease prevention trials. Biometrika 1986; 73(1):1–11.

24. Barlow WE, Ichikawa L, Rosner D, Izumi S. Analysis of case-cohort designs. J Clin Epidemiol. 1999; 52(12):1165–72. PMID: 10580779.

25. Williams B, Williams AJ, Anderson ST. Vitamin D deficiency and insufficiency in children with tuberculosis. Pediatr Infect Dis J. 2008; 27(10):941–2. doi: 10.1097 INF.0b013e31817525df PMID: 18776821.

26. Zeng J, Wu G, Yang W, Gu X, Liang W, Yao Y, et al. A serum vitamin d level <25nmol/l pose high tuberculosis risk: a meta-analysis. PLoS One. 2015; 10(5):e0126014. doi: 10.1371/journal.pone.0126014 PMID: 25938683; PubMed Central PMCID: PMC4418705.

27. Misra M, Paucaud D, Petryk A, Collett-Solberg PF, Kappy M, Drug, et al. Vitamin D deficiency in children and its management: review of current knowledge and recommendations. Pediatrics. 2008; 122(2):398–417. doi: 10.1542/peds.2007-1894 PMID: 18676559.

28. The South African National Tuberculosis Control Program: Practical Guidelines 2004.
29. Clopper CJ, Pearson ES. The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika. 1934; 26(4):404–13.

30. Marck SD, Katki HA. Specifying and implementing nonparametric and semi-parametric survival estimators in two-stage (sampled) cohort studies with missing case data. J Amer Statist Assoc. 2006; 101:460–71.

31. Gutierrez MG, Master SS, Singh SB, Taylor GA, Colombo MI, Deretic V. Autophagy is a defense mechanism inhibiting BCG and Mycobacterium tuberculosis survival in infected macrophages. Cell. 2004; 119(6):753–66. doi: 10.1016/j.cell.2004.11.038 PMID: 15607973.

32. Singh SB, Davis AS, Taylor GA, Deretic V. Human IRGM induces autophagy to eliminate intracellular mycobacteria. Science. 2006; 313(5792):1438–41. doi: 10.1126/science.1129577 PMID: 16888103.

33. Poopesi MA, Norris SA, Pettifor JM. Factors influencing the vitamin D status of 10-year-old urban South African children. Public Health Nutr. 2011; 14(2):334–9. doi: 10.1017/S136898001000234X PMID: 20804632.

34. Campbell GR, Spector SA. Vitamin D inhibits human immunodeficiency virus type 1 and Mycobacterium tuberculosis infection in macrophages through the induction of autophagy. PLoS Pathog. 2012; 8(5):e1002689. doi: 10.1371/journal.ppat.1002689 PMID: 22589721; PubMed Central PMCID: PMC3349755.

35. Deluca HF. History of the discovery of vitamin D and its active metabolites. Bonekey Rep. 2014; 3:479. doi: 10.1038/bonekey.2013.213 PMID: 24466410; PubMed Central PMCID: PMC3899558.

36. Chapman SJ, Hill AV. Human genetic susceptibility to infectious disease. Nat Rev Genet. 2012; 13(3):175–88. doi: 10.1038/nrg3114 PMID: 22310894.

37. Moller M, de Wit E, Hoal EG. Past, present and future directions in human genetic susceptibility to tuberculosis. FEMS Immunol Med Microbiol. 2010; 58(1):3–26. doi: 10.1111/j.1574-695X.2009.00600.x PMID: 19780822.

38. Moller M, Hoal EG. Current findings, challenges and novel approaches in human genetic susceptibility to tuberculosis. Tuberculosis. 2010; 90(2):71–83. doi: 10.1016/j.tube.2010.02.002 PMID: 20206579.

39. Selvaraj P, Harishankar M, Singh B, Jawahar MS, Banurekha VV. Toll-like receptor and TIRAP gene polymorphisms in pulmonary tuberculosis patients of South India. Tuberculosis (Edinb). 2010; 90(5):306–10. doi: 10.1016/j.tube.2010.08.001 PMID: 20797905.

40. Netea MG, Wijmenga C, O'Neill LA. Genetic variation in Toll-like receptors and disease susceptibility. Nat Immunol. 2012; 13(6):535–42. doi: 10.1038/ni.2284 PMID: 22610250.